Consensus statement on the use of alemtuzumab in daily clinical practice in Spain release_s6vf3wkswzbfnf2qrq5ci6lbru

by J.E. Meca-Lallana, M. Fernández-Prada, E. García Vázquez, S. Moreno Guillén, S. Otero Romero, M. Rus Hidalgo, L.M. Villar Guimerans, S. Eichau Madueño, Ó. Fernández Fernández, G. Izquierdo Ayuso, J.C. Álvarez Cermeño, C. Arnal García (+18 others)

Published in Neurología (English Edition) by Elsevier BV.

2020   Volume 37, Issue 8, p615-630

Abstract

Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis. A consensus document was drafted on the management of alemtuzumab in routine clinical practice in Spain. A group of multiple sclerosis specialists reviewed articles addressing treatment with alemtuzumab in patients with multiple sclerosis and published before December 2017. The included studies assessed the drug's efficacy, effectiveness, and safety; screening for infections and vaccination; and administration and monitoring aspects. The initial proposed recommendations were developed by a coordinating group and based on the available evidence and their clinical experience. The consensus process was carried out in 2 stages, with the initial threshold percentage for group agreement established at 80%. The final document with all the recommendations agreed by the working group was submitted for external review and the comments received were considered by the coordinating group. The present document is intended to be used as a tool for optimising the management of alemtuzumab in routine clinical practice.
In text/plain format

Archived Files and Locations

application/pdf  1.7 MB
file_a3sww7ygcjefpa5tonxxkdn2iu
pdf.sciencedirectassets.com (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2020-03-12
Language   en ?
Container Metadata
Open Access Publication
In DOAJ
In Keepers Registry
ISSN-L:  2173-5808
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: b0988365-3f3c-4d52-98e1-46641405b755
API URL: JSON